Sleep Disorders Pharmaceutical and Healthcare Pipeline Review 2017

Pune, India, 13th October 2017: WiseGuyReports announced addition of new report, titled “Sleep Disorders Drug Development Pipeline Review, 2017”.

Pune, India - October 13, 2017 /MarketersMedia/ —

Summary
This report provides an overview of the pipeline landscape for sleep disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Restless Legs Syndrome, Nocturia and Insomnia, and features dormant and discontinued projects.

Restless Legs Syndrome is a neurologic disorder with a core feature of a distressing, irresistible need or urge to move the legs. Risk factors for RLS include low iron levels, kidney failure, Parkinson's disease, diabetes mellitus, rheumatoid arthritis, and pregnancy.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2385279-sleep-disorders-drug-development-pipeline-review-2017

Nocturia, or nocturnal polyuria, describes the excessive urination during night time. Nocturia becomes more common with age and may be symptomatic of the use of diuretic substances, prescription drugs, edema from heart failure, insomnia, pain and prostate or bladder disorders.

Finally, insomnia is a sleep disorder that is characterized by difficulty in falling or staying asleep. Symptoms include difficulty falling asleep at night, waking up during the night, irritability, depression and anxiety.

The size of these pipelines ranges from eight products in restless legs syndrome and nocturia to 31 in insomnia. Across all three of these indications there is a diverse range of molecular targets due to the different pathologies of the indications. The most common targets for restless legs syndrome, nocturia and insomnia therapeutics are D2 dopamine receptor, vasopressin V2 receptor and orexin receptor, respectively.

Scope
- Which companies are the most active within the pipeline for sleep disorder therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of sleep disorders?

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Content: Key Points

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Sleep Disorders Report Coverage 7
2.2 Restless Legs Syndrome - Overview 7
2.3 Nocturia - Overview 7
2.4 Insomnia - Overview 7
3 Therapeutics Development 8
3.1 Restless Legs Syndrome 8
3.2 Nocturia 11
3.3 Insomnia 14
4 Therapeutics Assessment 21
4.1 Restless Legs Syndrome 21
4.2 Nocturia 27
4.3 Insomnia 33
5 Companies Involved in Therapeutics Development 39
5.1 Restless Legs Syndrome 39
5.2 Nocturia 42
5.3 Insomnia 44
6 Dormant Projects 53
6.1 Restless Legs Syndrome 53
6.2 Nocturia 53
6.3 Insomnia 54
7 Discontinued Products 56
7.1 Restless Legs Syndrome 56
7.2 Insomnia 56
8 Product Development Milestones 58
8.1 Restless Legs Syndrome 58
8.2 Nocturia 63
…Continued

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers
Phone: +91 841 198 5042

Source URL: https://marketersmedia.com/sleep-disorders-pharmaceutical-and-healthcare-pipeline-review-2017/250082

For more information, please visit http://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 250082

More News From thebudgetreport.com

The Latest: Mnuchin cautiously optimistic on trade

Apr 21, 2018

WASHINGTON — The Latest on the global finance meetings in Washington (all times local): 1:10 p.m. The International Monetary Fund's policymaking committee says a strong world economy is threatened by increasing tension over trade and a heavy global debt load. Officials say longer-term global prospects are clouded by sluggish productivity growth and aging populations in wealthy countries. Policymakers say in a statement at the end of three days of meetings that countries should take advantage of the broadest-based expansion in a decade and enact reforms that will make their economies more efficient. And cutting government debts is urged. The IMF...

Mnuchin expresses optimism for resolution of trade fights

Apr 21, 2018

WASHINGTON — Treasury Secretary Steven Mnuchin expressed cautious optimism Saturday over efforts to resolve trade tensions that have rattled financial markets and clouded the global economic outlook. Mnuchin held a string of meetings over the past three days with financial officials from China, Japan and Europe over the punitive tariffs the administration has unveiled in an effort to fulfill President Donald Trump's campaign promise to reduce America's huge trade deficits. In a session with reporters, Mnuchin refused to say how close the United States was to resolving the various trade disputes but did indicate progress was being made in the...

AP FACT CHECK: Trump's shifting rationale for firing Comey

Apr 21, 2018

WASHINGTON — President Donald Trump offered a shifting rationale this past week for his firing of FBI Director James Comey and joined other Republicans in exaggerating how much simpler it will become for Americans to file their taxes next time. He also erred, though by just a hair, in claiming a historic achievement in black and Hispanic joblessness. A look behind recent statements on these matters and more: TRUMP: "Slippery James Comey, the worst FBI Director in history, was not fired because of the phony Russia investigation where, by the way, there was NO COLLUSION (except by the Dems)!" —...

Army lowers 2017 recruiting goal; more soldiers staying on

Apr 21, 2018

WASHINGTON — The U.S. Army will not meet its mission to recruit 80,000 active duty soldiers this year and has officially lowered that goal. But Army leaders said the service has been able to encourage more experienced service members to stay on the job to satisfy a growing demand for troops. Army Sgt. Maj. Daniel Dailey said Friday that the updated goal will be 76,500. Six months into the recruiting year, the service has brought in just 28,000 new soldiers. Dailey said the goal is to grow the Army to 483,500, as approved by Congress, and it's up to the...

Slumping tech companies weigh on US stocks

Apr 21, 2018

A steep slide in technology companies weighed on U.S. stocks Friday, pulling the market lower for the second day in a row. Losses among retailers, packaged food and beverage makers and other consumer goods companies also helped weigh down the market. Banks rose as bond yields continued to climb, reflecting increasing investor concerns of higher inflation in the wake of rising oil and other commodity prices. "Higher commodity prices, a little bit more inflation pressure and higher interest rates, that sort of takes some wind out of the sails for equity markets, at least short-term," said Edward Campbell, senior portfolio...

The Budget Report seeks to provide comprehensive coverage and analysis on the current economic, financial issues around the world. First hand finance and economic news all day, every day.

Contact us: sales@thebudgetreport.com